Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Yahoo! Finance
islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived therapy, as a one-time treatment for patients with type 1 diabetes, with a goal of normal blood glucose, with no insulin and no immunosuppression Made significant progress with SC451 across manufacturing, regulatory, and clinical trial preparedness, including the non-clinical testing plan and manufacture of the master cell bank Expect to file investigational new drug application (IND) for SC451 in type 1 diabetes and begin Phase 1 trial as early as this year Expect to generate first-in-human data in blood cancers as early as this year for the next-generation in vivo CAR T product candidate, SG293,
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology (SANA) had its price target lowered by HC Wainwright from $9.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesGlobeNewswire
- Sana Biotechnology, Inc. (SANA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology to Present at March 2026 Investor Conferences [Yahoo! Finance]Yahoo! Finance
SANA
Earnings
- 8/11/25 - Beat
SANA
Sec Filings
- 3/3/26 - Form S-3ASR
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- SANA's page on the SEC website